Imbed Biosciences has filed a notice of an exempt offering of securities to raise $6,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Imbed Biosciences is raising $6,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Ankit Agarwal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Imbed Biosciences
Imbed Biosciences Inc. is a privately held medical device company emerging as a leader in the development of advanced therapies for the treatment of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte Matrix technology that presents bioactive molecules on tissue surfaces to combat local pain and infections. The microscale matrix accelerates cell migration and reduces antibiotic/opioid abuse. Company is registered with U.S. FDA as a medical device manufacturer and maintains an ISO 13485 certified Quality Management System.
To learn more about Imbed Biosciences, visit http://imbedbio.com/
Contact:
Ankit Agarwal, President and Chief Executive Officer
888-472-9898
https://www.linkedin.com/in/ankit-agarwal-414a606/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.